Microbiome and Sarcopenia in Patients With Liver Cirrhosis

Microbiome and Sarcopenia in Patients With Liver Cirrhosis: A Prospective Controlled Cohort Study

Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70% of cirrhotic patients. Malnutrition and sarcopenia are associated with an increased risk of complications and mortality.

In cirrhosis the gut microbiome is altered leading to increased gut permeability, bacterial translocation and inflammation. Since the microbiome is involved in nutrient uptake and metabolism, it is hypothesized that microbiome alterations contribute to sarcopenia. A prospective controlled cohort study to investigate the interrelation of microbiome changes and sarcopenia in cirrhosis will be conducted. Furthermore the effect of nutritional interventions on the microbiome in cirrhosis will be studied. From this study information on how the gut microbiome composition and sarcopenia are associated in cirrhosis and if modulation of the gut microbiome by nutritional interventions is feasible will be collected.

Study Overview

• Status: Recruiting
• Conditions: Liver Cirrhosis; Sarcopenia
• Intervention / Treatment: Dietary supplement: Fresubin energy

Detailed Description

Scientific background

Protein-energy malnutrition (PEM) occurs in 65-90% of patients with chronic liver disease. PEM is caused by various factors including poor dietary intake, loss of appetite, decreased hepatic protein synthesis, malabsorption and hypermetabolism. It is associated with an increased risk of complications including ascites, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome and mortality. There is a direct relation between the progression of the liver disease and the severity of malnutrition.

Malnutrition and sarcopenia in liver cirrhosis patients

PEM leads to sarcopenia as a common, but frequently overlooked, complication. Sarcopenia is defined as a decrease in muscle mass two standard deviations below the healthy young adult mean. Sarcopenia is associated with aging, chronic diseases and malignancy. To determine the severity of muscle wasting, computed tomography scan (CT) or magnetic resonance imaging (MRI) are an objective and reproducible technique. Sarcopenia negatively impacts on survival, correlates with the risk of infections, increases surgical risk and leads to a poor quality of life. Besides PEM also inflammation is of importance in the development of sarcopenia.

Diversity in the microbiome in patients with liver cirrhosis and association with sarcopenia.

The gut microbiome of liver cirrhosis patients is altered compared to healthy individuals. Dysbiosis leads to an increased gut permeability, bacterial translocation and inflammation. This contributes to fibrogenesis and may also be related to hepatocarcinogenesis. Hence, new treatment approaches in cirrhosis focus on changing the microbial landscape.

Modulation the gut microbiome may also be a strategy to reverse sarcopenia by reducing systematic inflammation.

Hypothesis and aims

There is an association between gut microbiome composition, gut permeability and the existence of sarcopenia in cirrhotic patients.

Primary hypothesis: Diversity of the gut microbiome is reduced in liver cirrhosis patients with sarcopenia compared to those without sarcopenia or healthy controls.

Secondary hypotheses: There is an association between gut microbiome composition, biomarker of gut permeability and bacterial translocation with the presence of sarcopenia in cirrhosis. Oral nutrition supplements (ONS) can influence the composition of the gut microbiome, gut permeability, bacterial translocation and inflammation. Sarcopenia can be diagnosed from patients portraits.

Aims: to investigate:

• the composition of the gut microbiome
• biomarkers of gut permeability, bacterial translocation and inflammation
• the incidence and severity of sarcopenia
• the impact of oral nutrition supplements (ONS) on the gut microbiome
• whether artificial intelligence can be used to diagnose sarcopenia from face portraits.

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Vanessa Stadlbauer-Köllner, AssocProf Dr; Phone Number: +4331638582282; Email: vanessa.stadlbauer@medunigraz.at
• Study Contact Backup: Name: Julia Haberl, BSc; Phone Number: +4331638580777; Email: julia.haberl@klinikum-graz.at

Study Locations

• Austria
  • Graz, Austria
    • Recruiting
    • Medical University Graz
    • Contact: Vanessa Stadlbauer-Köllner, MD; Phone Number: 82282 0043 316 385; Email: vanessa.stadlbauer@medunigraz.at

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Hospitalized patients for any reason with clinical/radiological/histological diagnosis of cirrhosis
• Age >18y
• Informed consent
• CT/MRI scan within +/-14 days of the baseline study visit

Exclusion Criteria:

• Hepatic encephalopathy > grade 2 and or other cognitive disorder not allowing informed consent
• advanced hepatocellular carcinoma
• Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cirrhosis + sarcopenia; Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.	Dietary supplement: Fresubin energy; dietary protein energy supplement
No Intervention: Control; Patients with sarcopenia and no evidence of cirrhosis and healthy controls

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Alpha diversity	16s rDNA sequencing of the stool microbiome	day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Zonulin	ELISA	day 1
diamino-oxidase	ELISA	day 1, day 7
Calprotectin	ELISA	day 1
Gut permeability	marker panel	change between day 1 and day 7
taxonomic composition of the microbiome	16s rDNA sequencing of the stool microbiome	day 1
taxonomic composition of the microbiome	16s rDNA sequencing of the stool microbiome	change between day 1 and day 7
lipopolysaccharide	HEK blue cell assay	day 1
sCD14	ELISA	day 1
lipopolysaccharide binding protein	ELISA	day 1
bacterial DNA	HEK blue cell assay	day 1
bacterial translocation	marker panel	change between day 1 and day 7
cytokine panel	Bead array	day 1
carboxylated proteins	ELISA	day 1
advanced oxidation end products	ELISA	day 1
inflammation	marker panel	change between day 1 and day 7
myostatin	ELISA	day 1
fibroblast growth factor 21	ELISA	day 1
insulin like growth factor 1	ELISA	day 1
Irisin	ELISA	day 1
nutritional status	Questionnaire	day 1
Sarcopenia	MR/CT scan	day 1
face portrait	face portraits "selfies" will be obtained and AI algorithms will be used to diagnose sarcopenia from selfies	day 1

Collaborators and Investigators

• Sponsor: Medical University of Graz

Study record dates

Study Major Dates

• Study Start (Actual): April 11, 2017
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: March 1, 2017
• First Submitted That Met QC Criteria: March 14, 2017
• First Posted (Actual): March 15, 2017

Study Record Updates

• Last Update Posted (Actual): October 9, 2024
• Last Update Submitted That Met QC Criteria: October 7, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Microbiome; Sarcopenia; Liver cirrhosis
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Liver Diseases; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Fibrosis; Liver Cirrhosis; Sarcopenia
• Other Study ID Numbers: SAR (Swedish Arthroplasty Register)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No